Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Tacke

Showing results (11-20 of 860) with videos related to

Pageof 86
Sort By:
Hepatitis Monthly|February 7, 2012
Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patientsFrank Tacke
Hepatology (Baltimore, Md.)|December 6, 2011
Infiltrating monocytes versus resident Kupffer cells: do alternatively activated macrophages need to be targeted alternatively?Frank Tacke, Christian Kurts
Gut|April 28, 2022
Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturityMichael Dudek, Frank Tacke
Gut|September 18, 2025
Dissecting the immune pathogenesis of HBV-ACLF through single-cell multimodal analysisFrank Tacke, Jonel Trebicka
Annals of Translational Medicine|May 14, 2021
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and preventionFrank Tacke, Ralf Weiskirchen
Hepatology (Baltimore, Md.)|December 25, 2016
From NAFLD to HCC: Is IL-17 the crucial link?Maximilian Hatting, Frank Tacke
The Journal of Endocrinology|October 19, 2022
Treating inflammation to combat non-alcoholic fatty liver diseaseLeke Wiering, Frank Tacke
Journal of Hepatology|January 17, 2025
The Journal of Hepatology: A new team at 40Vlad Ratziu, Frank Tacke
Hepatology (Baltimore, Md.)|August 22, 2023
Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver diseaseMoritz Peiseler, Frank Tacke
Hepatology (Baltimore, Md.)|March 30, 2007
Causes of death in hepatitis B and/or C virus infected-people - lessons for clinical practiceFrank Tacke, Christian Trautwein
Pageof 86

Showing results (11-20 of 860) with videos related to

Sort By:
Pageof 86
Hepatitis Monthly|February 7, 2012
Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patientsFrank Tacke
Hepatology (Baltimore, Md.)|December 6, 2011
Infiltrating monocytes versus resident Kupffer cells: do alternatively activated macrophages need to be targeted alternatively?Frank Tacke, Christian Kurts
Gut|April 28, 2022
Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturityMichael Dudek, Frank Tacke
Gut|September 18, 2025
Dissecting the immune pathogenesis of HBV-ACLF through single-cell multimodal analysisFrank Tacke, Jonel Trebicka
Annals of Translational Medicine|May 14, 2021
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and preventionFrank Tacke, Ralf Weiskirchen
Hepatology (Baltimore, Md.)|December 25, 2016
From NAFLD to HCC: Is IL-17 the crucial link?Maximilian Hatting, Frank Tacke
The Journal of Endocrinology|October 19, 2022
Treating inflammation to combat non-alcoholic fatty liver diseaseLeke Wiering, Frank Tacke
Journal of Hepatology|January 17, 2025
The Journal of Hepatology: A new team at 40Vlad Ratziu, Frank Tacke
Hepatology (Baltimore, Md.)|August 22, 2023
Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver diseaseMoritz Peiseler, Frank Tacke
Hepatology (Baltimore, Md.)|March 30, 2007
Causes of death in hepatitis B and/or C virus infected-people - lessons for clinical practiceFrank Tacke, Christian Trautwein
Pageof 86